BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38623572)

  • 1. Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review.
    Sanyal AJ; Husain M; Diab C; Mangla KK; Shoeb A; Lingvay I; Tapper EB
    Am Heart J Plus; 2024 May; 41():100386. PubMed ID: 38623572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
    Li C; Wang T; Song J
    Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
    Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
    Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Targher G; Byrne CD; Tilg H
    Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
    Zeng J; Fan JG; Francque SM
    United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022).
    Kouvari M; Chrysohoou C; Damigou E; Barkas F; Kravvariti E; Liberopoulos E; Tsioufis C; Sfikakis PP; Pitsavos C; Panagiotakos D; Mantzoros CS;
    Clin Nutr; 2024 Mar; 43(3):900-908. PubMed ID: 38387279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients.
    Paklar N; Mijic M; Filipec-Kanizaj T
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIS2+
    Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality, Hepatic Decompensation, and Cardiovascular- and Renal-Related Outcomes in Lean Versus Non-lean Patients Hospitalized With Metabolic Dysfunction-Associated Steatohepatitis (MASH).
    Ezeani C; Omaliko C; Al-Ajlouni YA; Njei B
    Cureus; 2024 May; 16(5):e60968. PubMed ID: 38915982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Muddle. MASLD and MASH on the Horizon.
    Meagher T
    J Insur Med; 2023 Jul; 50(2):147-149. PubMed ID: 38358924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
    Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
    Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.